Effect of Escitalopram vs. Reboxetine on Somatic and Visceral Sensitivity of Patients With Major Depressive Disorder: a Randomized, Double Blind Clinical Trial
Phase of Trial: Phase IV
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Escitalopram (Primary) ; Reboxetine
- Indications Abdominal pain; Major depressive disorder
- Focus Pharmacodynamics; Therapeutic Use
- 26 May 2010 Planned end date changed from 1 Jun 2009 to 1 Apr 2011 as reported by ClinicalTrials.gov.
- 01 Aug 2006 Status change
- 26 Nov 2005 New trial record.